There are several therapies for treating lupoid leishmaniasis. We compared the effectiveness of intralesional meglumine antimoniate (MA) and topical application of trichloroacetic acid (TCA) 50% solution.
Methods:
This study was a randomized clinical trial comprising 60 lupoid leishmaniasis patients. The first group received intralesional MA once a week, and the second group was treated once weekly with TCA 50% topical solution. The results were recorded once after 8 weeks and then 3 months after the termination of treatment.
Results:
The total clearance rates after treatment and after the 3-month follow-up were, respectively, 48.1% and 40% in the first group and 44.4% and 36.6% in the second group. There was no significant difference between the two treatment groups (p = .25 and p = .26). In both groups, the most common side effect was scarring.
Conclusion:
Having almost the same efficacies, TCA as a topical approach could be as effective as MA in the lupoid leishmaniasis treatment plan.
Get full access to this article
View all access options for this article.
References
1.
ChristophersonJB. Leishmaniasis of the skin resembling lupus vulgaris. Proc R Soc Med1923;16(Dermatol Sect):48–50.
2.
BowlingJCVega-LopezF. Case 2. Lupoid leishmaniasis. Clin Exp Dermatol2003;28:683–4, doi:10.1046/j.1365-2230.2003.01420.x.
3.
GurelMSUlukanligilMOzbilgeH. Cutaneous leishmaniasis in Sanliurfa: epidemiologic and clinical features of the last four years (1997–2000). Int J Dermatol2002;41:32–7, doi:10.1046/j.0011-9059.2001.01396.x.
4.
ValizadehMDalimi AslHFataA. A study on Leishmania species causing cutaneous leishmaniasis in Mashhad using specific monoclonal antibodies. Modares J Med Sci2005;7:107–13.
5.
GonzalezUPinartMReveizL. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev2008;(4):CD005067.
6.
BarrettMPCroftSL. Management of trypanosomiasis and leishmaniasis. Br Med Bull2012;104:175–96, doi:10.1093/bmb/lds031.
7.
MomeniAZAminjavaheriM. Treatment of recurrent cutaneous leishmaniasis. Int J Dermatol1995;34:129–33, doi:10.1111/j.1365-4362.1995.tb03598.x.
8.
GanorS. The treatment of leishmaniasis recidivans with local injections of amphotericin B. Dermatol Int1967;6:141–3, doi:10.1111/j.1365-4362.1967.tb05251.x.
9.
BabajevKBBabajevOGKorepanovVI. Treatment of cutaneous leishmaniasis using a carbon dioxide laser. Bull World Health Organ1991;69:103–6.
10.
EissaMMSolimanASNassarSO. Ultrastructural and immunological features of experimental cutaneous leishmaniasis after treatment with intralesional hypertonic sodium chloride and CO2 laser rays. J Egypt Soc Parasitol2003;33:329–52.
11.
MoslehIMGeithENatshehL. Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. J Am Acad Dermatol2008;58:617–24, doi:10.1016/j.jaad.2007.12.032.
12.
ReithingerRMohsenMWahidM. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin Infect Dis2005;15:40:1148–55, doi:10.1086/428736.
13.
NilforoushzadehMASadeghianGJaffaryF. Successful treatment of lupoid cutaneous leishmaniasis with Glucantime and topical trichloroacetic acid (a case report). Korean J Parasitol2008;46:175–7, doi:10.3347/kjp.2008.46.3.175.
14.
NilforoushzadehMAJaffaryFReiszadehMR. Comparative effect of topical trichloroacetic acid and intralesional meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Int J Pharmacol2006;2:633–6, doi:10.3923/ijp.2006.633.636.
15.
LawrenceNLeonhardtJM. Trichloroacetic acid (TCA) peels. In: RubinMGDoverJSAlamM editors. Chemical peels. 9th ed.Philadelphia: Elsevier; 2006. p. 77–8.
16.
PezeshkpoorFBanihashemiMYazdanpanahMJ. Comparative study of topical 80% trichloroacetic acid with 35% trichloroacetic acid in the treatment of the common wart. J Drugs Dermatol2012;11:e66–9.
17.
ChunEYLeeJBLeeKH. Focal trichloracetic acid peel method for benign pigmented lesions in dark-skinned patients. Dermatol Surg2004;30:512–6, doi:10.1111/j.1524-4725.2004.30166.x.
18.
SezerEErbilHKurumluZ. A comparative study of focal medium-depth chemical peel versus cryosurgery for the treatment of solar lentigo. Eur J Dermatol2007;17:26–9.
19.
KhungerN. Standard guidelines of care for chemical peels. Indian J Dermatol Venereol Leprol2008;74Suppl:S5–12.
20.
ZanottiKMBelinsonJ. Update on the diagnosis and treatment of human papillomavirus infection. Cleve Clin J Med2002;69:948, 951–5, doi:10.3949/ccjm.69.12.948.
21.
NajimRASharquieKEAl-ZubaidySA. Possible mechanisms of action of the compounds injected intralesionally in the treatment of cutaneous leishmaniasis, in addition to their direct effects on the parasites. Ann Trop Med Parasitol2006;100:33–8, doi:10.1179/136485906X78472.
22.
FarahFSSamraSANuwayri-SaltiN. The role of the macrophage in cutaneous leishmaniasis. Immunology1975;29:755–64.
23.
MurrayHWBermanJDDaviesCR. Advances in leishmaniasis. Lancet2005;366:1561–77, doi:10.1016/S0140-6736(05)67629-5.
KhatamiAFiroozAGorouhiF. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol2007;57:335, doi:10.1016/j.jaad.2007.01.016.
26.
MurrayHWBermanJDDaviesCR. Advances in leishmaniasis. Lancet2005;366:1561–77, doi:10.1016/S0140-6736(05)67629-5.
27.
CroftSLSeifertKYardleyV. Current scenario of drug development for leishmaniasis. Indian J Med Res2006;123:399–410.
